|
Proteome Sciences PLC on Friday said it has won a contract from a US biopharmaceutical company worth over $1 million. The London-based protein-focused drug development services provider did not disclose the name of the client and said the contract is for its mass spectometry services to analyse samples in an ongoing clinical trial. Proteome Science shares were up 4.7% to 4.70 pence in London on Friday morning. The firm said a significant proportion of the work should be completed in the current financial year and into 2026. It will use the Good Clinical Laboratory Practice accreditation that Proteome obtained, it said. Chief Commercial Officer Richard Dennis said: ‘In April 2024 we announced the first contract from this customer and commented that we expected additional contracts to be received from them in the near future. This contract represents a further targeted assay that we will perform under GCLP compliance to monitor drug performance in an ongoing clinical trial. As in 2024 we are seeing increasing interest for GCLP work from other major biopharma clients in both the US and Europe and expect additional orders to follow in 2025.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
